



PRESS RELEASE

Published: 13-11-2023

Inhalation Sciences wins new purchase order worth 276,450 Euro (3.2 MSEK)

(Stockholm, Sweden, 13 November, 2023) **Inhalation Sciences AB has received a new purchase order worth 276,450 Euro from a returning customer, a large European pharma company with a substantial pipeline of inhaled therapies. The order is for ISAB's aerosol generating platform PreciseInhale and its unique cell exposure module.**

The returning client is a loyal customer and has long been a keen advocate of ISAB's unique multi-modular, precision dosing aerosol system PreciseInhale. Within inhalation the customer has an extensive, competitive portfolio and robust pipeline.

PreciseInhale – reducing risk and costs

PreciseInhale is unique within inhaled drug development as a 'precision dosing' system. Unlike standard 'tower testing' systems, it customizes the individual aerosol dose to individual test animals. This achieves exceptionally high-precision and predictive data in the preclinical stages, so reducing risk and costs in later clinical stages.

Leading the way in *in vitro* testing

The advantages of *in vitro* testing are becoming increasingly understood in inhalation drug development. *In vitro* dissolution methods like the ones designed by ISAB can generate predictive IVIVC (*in vitro in vivo* correlated) data early on that enable poor Drug Candidates to be eliminated, reducing costs and accelerating development.

CEO Manoush Masarrat: "it is a great validation when an existing customer returns once again. This time to purchase another main platform system and a new test module. We are grateful for their continued confidence in our products - and proud that our technology has made a positive contribution to their impressive inhalation portfolio".

For more information about Inhalation Sciences, please contact:

Manoush Masarrat, CEO

E-mail: Manoush.masarrat@inhalation.se

Mobile: +46 (0)73 628 9153

About Inhalation Sciences Sweden AB (publ)

Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments and services for research into inhalation. The company's patented lab instruments PreciseInhale® and DissolvIt® enable researchers in the pharma industry to

make drug pipeline decisions at an early stage, saving time and resources for R&D departments, and enables researchers in academic institutions to define how aerosols and small particles impact our lungs, and so our health, when being inhaled.

The information above was provided by Inhalation Sciences Sweden AB according to EU Market Abuse Regulations. The information was provided, through the above contact person, for publication on 13 November 2023.